MANAGEMENT TEAM & BOARD OF DIRECTORS
ADVISORY BOARD TEAM
John Erban, MD
Tufts Cancer Center Professor
Tufts University School of Medicine
Steven E. Harms, MD, FACR, FSBI
Steven E. Harms, MD, FACR is recognized nationally in the area of magnetic resonance imaging (MRI). He was formerly on the faculty at the University of Arkansas for Medical Sciences (UAMS), Baylor University Medical Center in Dallas, and M. D. Anderson Cancer Institute. During his 14 years as director of MRI at Baylor, Dr. Harms and his research team developed numerous MRI applications including TMJ, knee, orbit and RODEO Breast MRI.
He is the former president of the Society of Magnetic Resonance in Medicine and received the AMA William Beaumont Award in 1995 (annually awarded to the outstanding physician in the nation under the age of 50). Harms was named “Komen Foundation Scientist of the Year” by Susan G. Komen for the Cure in 1998. He has authored over 116 scientific papers, 43 book chapters, and 11 patents. He was on the committee that wrote the current American Cancer Society breast cancer screening guidelines, which recommends breast MRI screening for high-risk patients. He was on the Board of Directors of the Society of Magnetic Resonance in Medicine (past-President) and the American Society of Breast Disease. He was served as a member and chairman of the Medical Devices Panel of the US Food and Drug Administration for over 17 years. He was awarded Fellow in the American College of Radiology and the Society of Breast Imaging. Harms practices at The Breast Center of Northwest Arkansas in Fayetteville, Arkansas a part of a larger multi-speciality practice, Medical Associates of Northwest Arkansas where he is a member of the executive committee and secretary and is Clinical Professor of Radiology at the University of Arkansas for Medical Sciences.
Tsung-Lung Yang, MD, Chief Innovation Officer Kaohsiung Veterans General Hospital Originals & Enterprises
Tsung-Lung Yang received his Medical Doctor degree from School of Medicine, National Yang-Ming University, Taipei, Taiwan, in 1991 and completed his resident radiologist training at Kaohsiung Veterans General Hospital ( KSVGH) in 1997, then after one-year radiologist fellowship, became staff radiologist in 1998, and was promoted as the section chief in Teleradiology since 2007. He was the architect for building the enterprise-wide PACS (picture archiving and communication system) at KSVGH since
1998 and successfully transformed the traditional client-server PACS into a browser-server medical information platform in 2006 (solution name was dubbed H.E.L.P. representing Healthcare Enhancement and Leverage Platform) using private cloud solution. In 2011, he was the major contributor to help KSVGH to win her best government service award of the year and won the honor of best five IT medical institute of the year in Asia of FutureGov as well. In 2017, he also created a brand new system called AIS, an abbreviation for Application Information System, as a secure bridging service from HIS-PACS-RIS complex to reach patients to reduce medical illiteracy by providing Chinese-based infographic reports via an unique App on mobile devices, called 高榮乳篩 in Chinese and eMiqlat in English. His research interests include breast imaging, abdominal radiology, radiological informatics, radiomics, nursing informatics, electronic medical record, virtual reality for medicine and semantic web solutions for future medical platform services.
He was promoted as chief innovation officer to lead an unprecedented unit: KSVGH Originals and Enterprises to connect more people to drive innovation.
Jinping Liu Clinical Director, Oncology Department, Sichuan Provincial People’s Hospital & Sichuan Academy of Medical Sciences. Professor, University of Electronic Science and Technology of China School of Medicine
Dr. Jinping Liu has been a surgeon at Sichuan Provincial People’s Hospital (“SPPH”) and Sichuan Academy of Medical Science since 1985 and a dedicated breast surgeon since 1992. He became Director of Breast Department in 2004 and Director of Oncology Department since 2013. Under Dr. Liu’s leadership, SPPH established the first dedicated breast surgical specialty and implemented multidisciplinary in breast treatment
program in Sichuan. He closely followed the most cutting-edge trends in the world to advance better practice in the Department. He took initiatives to reform breast surgeries from traditional, extended or modified radical mastectomy to lumpectomy with confirmation from sentinel lymph node biopsy. Dr. Liu also champion in onco-plastic surgery, neoadjuvant chemotherapy, adjuvant chemotherapy, and biological targeted therapy.
Dr. Liu has also devoted to research aside from his clinical dedication. His research team established the first breast tumor biological sample tissue bank and built a thorough follow-up system post treatment. He participated in many multicenter clinical trials internationally and China’s national new drug registration clinical trials. Dr. Liu actively served many other roles in nation-renowned and world-known institutions, such as American ASCO, ATLAS clinical trial collaboration group in UK, executive member at training expert committee of Chinese Medical Association and Breast Professional Committee of China Medical Education Association, to name a few. Dr. Liu finished his bachelor’s degree from Luzhou Medical College (former of Southwest Medical University), and master’s degree at Sichuan University Medical School. He has been a professor at School of Medicine, University of Electronic Science and Technology of China since 2005.
Harris Berman, MD Dean, Tufts University School of Medicine
Professor, Public Health and Community Medicine
Harris A. Berman, MD is Dean of Tufts University School of Medicine, Professor of Medicine, and Professor of Public Health and Community Medicine. Prior to that, he was Vice Dean of the Medical School, and Dean of Public Health and Professional Degree Programs and Chair of the Department of Public Health and Family Medicine. Before coming to Tufts University he was a pioneer in the development of managed care in New England, and for 17 years, the CEO of the Tufts Health Plan.
Prior to joining Tufts Health Plan, Dr. Berman co-founded the Matthew Thornton Health Plan in Nashua, NH in 1971, one of the first HMOs in New England. He is currently a member of the Board of Directors of Tufts Medical Center, and its parent company, Wellforce, and until recently, of Tufts Health Plan.
Dr. Berman has international experience as a Peace Corps Physician in India and a consultant to the U.S. Agency for International Development in several international projects. At Tufts, he has spearheaded the expansion of the Global Health Program, and has helped grow the affiliation between Tufts and Christian Medical College in Vellore, South India, into many new areas of cooperation. As Dean of the medical school, he has been forging relationships for Tufts with institutions and funders in Taiwan, Singapore, Macau and China.
A graduate of Harvard College and Columbia University College of Physicians and Surgeons, Dr. Berman served as a resident on the Harvard Medical Service of Boston City Hospital and at Tufts Medical Center, and an Infectious Disease fellowship at Tufts Medical Center. He is a Fellow of the American College of Physicians.
Aaron Ciechanover, Ph.D., Nobel Laureate
Professor, Technion–Israel Institute of Technology
Prof. Aaron Ciechanover is a distinguished research professor in the Technion - Israel Institute of Technology in Haifa. He received his M.Sc. (1971) and M.D. (1973) from the Hebrew University in Jerusalem. He then completed his national service (1973-1976) as a military physician, after which he continued his studies and obtained his doctorate degree in biological sciences in the Faculty of Medicine in the Technion (D.Sc. 1982). At that time, Prof. Aaron Ciechanover was a graduate student under
Dr. Avram Hershko and in collaboration with Dr. Irwin A. Rose from the Fox Chase Cancer Center in Philadelphia, USA, when they discovered that covalent attachment of ubiquitin to a target protein signals it for degradation. After deciphering the mechanism of conjugation, they described the general proteolytic functions of the system and proposed a model according to which this modification serves as a recognition signal for a specific downstream protease. Along the years it has become clear that ubiquitin-mediated proteolysis plays major roles in numerous cellular processes, and aberrations in the system underlie the pathogenetic mechanisms of many diseases, among them certain malignancies and neurodegenerative disorders. Consequently, the system has become an important platform for drug development.
Besides the Nobel prize in chemistry, Ciechanover received the 2000 Albert Lasker Award and the 2003 Israel Prize. He is also a member of the Israeli National Academy of Sciences and Humanities, the American Academy of Arts and Sciences (Foreign Fellow), the American Philosophical Society, the National Academy of Sciences of the USA and the Institute of Medicine of the National Academies of the USA (Foreign Associate), the Pontifical Academy of Sciences at the Vatican, the Chinese Academy of Sciences (CAS; Foreign Member), and the Russian Academy of Sciences (Foreign Member).
Shaoping Deng President, Sichuan Provincial People’s Hospital
Shaoping Deng is President of Sichuan Provincial People’s Hospital. He has been dedicated to the research of organ transplantation and diabetes for 27 years, with outstanding clinical and scientific achievements. He has published over 100 articles in international journals, including Natural Medicine, The Journal of Clinical Investigation, Diabetes, Transplantation Proceedings.
Dr. Deng serves as editorial board member of Diabetes, American Journal
of Transplantation, Transplant International, Xenotransplantation, Chinese Hospital CEO and judge of The National Natural Science Fund. He is widely recognized as the academic authority of organ transplantation, especially pancreatic islets transplantation in diabetes treatment.
After returning to China in 2009, Dr. Deng put forward the concept of medical conjoined trusteeship model for hierarchical medical system to carry out hospital management. He promoted "medical treatment + Internet” for hospital to join the initiative health industry alliance (the only public hospital). He is committed to creating patients-centered medical environment with pervasive, fair and public welfare medical resources, leading hospital staff to respond to the call of national medical reform and constantly opening up a new pattern of hospital reform and development.
Yuanli Liu, Ph.D. Proofessor and Dean, Peking Union School of Public Health (PUSPH) President, Chinese Aging Well Association
Founding Director Harvard School of Public Health (HSPH) China Initiative
Dr. Yuanli Liu，with a Public Health and economics training background, has been serving as Professor of Health Policy and Management and Dean of School of Public Health at the Chinese Academy of Medical Sciences & Peking Union Medical College since 2013. From 1993 to 2013, Dr. Liu worked at Harvard School of Public Health in the area of global health policy and practice. In 2003, he served as one of the founding faculty
members of a new doctoral major in health systems. From 2005 to 2015, he served as the founding director of Harvard China Health Initiative, responsible for organizing series of applied research studies, senior executives education program and high-level policy dialogues targeting at the major health policy and development issues facing China and the U.S. Since returning back to his home country in 2013, Dr. Liu had been closely involved in China's healthcare reform and development initiatives as one of the leading policy advisers and organizers of top Think-Tank and social organizations. He currently serves as a member of the State Council Healthcare Reform Expert Committee, President of the Chinese Aging Well Association, Vice Chairman of the National Commission on Health Promotion and Education, a member of the National Commission for Development of Traditional Chinese Medicine, the National Commission for drafting the Essential Healthcare and Health Promotion Law. In 2017, Dr. Liu was named one of the top 50 most influential people in China with an overseas education and working background. He also has consulted for many international organizations including WHO, WB and Fortune 500 companies.
Jing Ma, MD, PhD Associate Professor Department of Population Medicine , Harvard Medical School President & Secretary-General, U.S.-China Health Summit
As a population scientist, Professor Ma studies cancer etiology, prediction, prevention, and intervention. She served as PIs and co-PIs of hundreds of million dollar research funds from NIH and published over 200 peer review research papers in the top scientific journals. Dr. Ma had served as the co-PI of the Harvard School of Public Health (HSPH) Project “Advancing Breast Cancer Awareness and Prevention in China”. She is recently invited by the Sichuan Provincial People’s Hospital to serve as the funding director of
their Center for Translational Medicine and Transformative Healthcare. Dr. Ma is currently working on establishing a China Center at the Department of Populational Medicine (DPM), Harvard Medical School, with the mission of improving health care delivery and population health through innovative research and teaching. Since 2013, she also serves as the President and Secretary-General of the U.S.-China Health Summit, which is dedicated to the advancement of global health by promoting the exchange of knowledge, ideas, and experiences of healthcare leaders from the U.S., China, and other countries through high-level strategic dialogues, leadership development programs, and applied research.
Liang Chuan (Jennifer) Chen President, St. Mary’s Hospital at Taitung, Taiwan
Ms. Chen is the President of St. Mary’s Hospital - Taitung, Taiwan. She has long dedicated herself to courses including: advancing preventive medicine, health promotion, and social welfare. She has been also committed to the generalization of survivors support, greatly initiating the campaign of building up “Breast Cancer Survivors Support Groups” in Taiwan. In 2002, Ms. Chen facilitated the establishment of the “Association of Taiwanese Breast Cancer Patients”, which becomes a significant service platform for breast cancer patients and survivors in
Taiwan. In 2008, the “Association of Taiwanese Diabetic Patients” was also founded thanks to the joint efforts from the society, which is a major alliance of diabetic patients across Taiwan and serves 495 diabetic patients support groups at present.
Ms. Chen started devoting herself to breast cancer prevention and treatment in Taiwan 30 years ago; she has given speeches and trainings over 1, 000 times throughout Taiwan. Her tireless efforts resulted in raising awareness of the prevention of breast cancer throughout the greater Chinese regions including Taiwan, Hong Kong and China. Five years ago, Aurora Breast Center was established in St. Mary's Hospital - Taitung. Thanks to her continuous efforts, a cutting-edge breast MRI system was introduced to the center which is the first in the world in establishment of comprehensive breast center using breast MRI to perform first line screening for the general public and created extraordinary results in high detection rate and significant improvement of breast cancer patients survival rate.
After years of practice, Ms. Chen along with Aurora Healthcare US Corp, established a good model for a comprehensive breast center covering services of education, screening, diagnosis, treatment, rehabilitation, patients and survivors supporting group, which was greatly recognized from the society and ready for wider application in China.
Prior to joining St. Mary’s Hospital -Taitung in Taiwan, Ms. Chen served as Executive Director of Catholic Sanipax Socio-Medical Service & Education Foundation (1985-2009), public health instructor at National Taipei University of Nursing and Health Sciences (1980-1985). Ms. Chen graduated from Department of Nursing at National Taipei University of Nursing and Health Sciences.
Da Hsuan Feng, Senior Fellow Institute for Advanced Studies of Nanyang Technological University Singapore
Chief Advisor China Silk iValley Research Institute
Feng’s career crisscrosses academia, industry and government. Born and grew up in Singapore, Dr. Da Hsuan Feng received his theoretical physics Ph.D. from the University of Minnesota (1972). He joined Drexel University in 1976, and became M. Russell Wehr Chair Professor in 1990. While at Drexel, he also served for two years as NSF Program Director in Theoretical Physics, a visiting professor of the University of Copenhagen Niels Bohr
Institute, the Institute which formulated quantum mechanics in the 20th century. From 1997-2000, he became Vice President of SAIC, aFortune 500 company where his portfolioranges from military to academia. In 2001, Feng assumed the Vice President for Research at the University of Texas at Dallas. From 2007-2017, Feng was the Senior Vice President of Cheng Kung University, Tsing Hua University in Taiwan, and Rector’s Special Advisor and Director of Global Strategies of Macau University, respectively.
Currently, Feng is a Senior Fellow of Singapore’s Nanyang Technological University’s (NTU) Institute of Advanced Studies. Today, NTU is the fastest growing university on the global landscape. He is also the Chief Advisor of China Silk iValley Research Institute, the top 6 among the China’s 600 Think-Tanks. He is now regarded as one of the experts in the implications of the belt and road initiative, and has been lecturing throughout Asia and North America.
Feng was bestowed the Fellow of the American Physical Society and is an honorary professor of fifteen Chinese universities and received the Bian-Zhong Award for Hubei Province 2009(年度湖北省编钟奖) and the “The Light of Civilization, the 2017 Chinese Cultural Exchange Award (文明之光·2017中国文化交流年度人物) award. He is a frequent editorial contributor to top Asian newspapers.
Feng consulted for Los Alamos, Oak Ridge and Brookhaven and UK’s Daresbury Laboratories. He was an Advisor to the Chairman of the House Armed Services Committee. He was also an honorary Board of Trustee of Nanjing University, a former member of Shantou University Board of Trustees, an Academic Advisory Board member of Malaysia’s Universiti Teknologi Petronas and Binus University in Indonesia. From 2005-2007, he was an independent board member of CellStar Board of Directors, a $1 Billion annual revenue global handset distribution company.
Professor Anli Shi Chairman, China Rehabilitation Society of CACA
Executive Chairman, Beijing Love Book Cancer Foundation
Vice General Secretary China Cancer Foundation
Professor Anli Shi has a lifetime dedication in China’s healthcare. She led many key non-for-profit organizations such as:
1. Chairman of China Rehabilitation Society of Cancer China Anti-Cancer Association(CACA),
2. Executive Chairman of Beijing Love Book Cancer Foundation,
3. Vice General Secretary for China Cancer Foundation,
4. Director of PAP Office which cooperates with world renowned pharmaceutical companies such as Pfizer, Roche, Johnson & Johnson,… etc.
5. Chairman of 18th Reach to Recovery, International Breast Cancer Support Conference in 2015,
6. Adviser on International Cooperative projects of Health Manpower Exchange Center, MOH.
Prior to this, Prof. Shi held many key government positions including the following:
Director for Health Standard Management and Chief for Division of Planning, China Ministry of Health (CMH)
1. Director of Division of International Exchange, CMH.
2. Vice-Director of Department of Medical Science-Technology and Education, CMH
3. Secretary General of 4th National Health Standard Technical Committee,
4. Board Member of Council of China Smoking and Health Association from 1976 to 2007.
Prof. Shi completed her medical education from Beijing Medical University and her Master degree from WHO’s Health Development in University of Leuven in Belgium.
Yongkai Weng President, Aixin Foundation
Dr. Yongkai Weng is President of the AiXin Foundation, a charity foundation established in the US. Dr. Weng graduated from Peking University in 1980, and received her Ph.D. in 1992 from Temple University in the US. She worked for the US FDA for 11 years in the research and regulatory field after completing her post-doctoral training at NCI in NIH.
From 1969 to 1975, Dr. Weng was a “barefoot doctor” and midwife in the impoverished areas of China. Her focus in HIV/AIDS prevention began
in 2001, the experience led to the founding of AiXin (Loving Heart) Foundation with a group of professionals in US and China committing to the mission to strengthening basic education and public health services in China’s rural areas with the hope to apply the accumulated experience to benefit other parts of the world.
In 2006, Dr. Weng took early retirement from the US FDA and returned to China. Since then she has supported a number of nationwide policy and advocacy initiatives in China. She has been actively involved in China’s healthcare reform, and has spearheaded some pilot programs in health education and promotion in rural China. Her extensive experience as a liaison to facilitate cooperation between state institutions, international organizations, and local and community based non-governmental organizations played a significant role in successful implementation of these programs.
In the 1980s, Dr. Hollingsworth was one of the earliest surgeons who transitioned to a breast-dedicated practice, who established one of the first multidisciplinary breast centers in the U.S. He was the First Holder of the G. Rainey Williams Chair of Surgical Breast Oncology at the University of Oklahoma.
After breast MRI was introduced into clinical practice, he transitioned to a practice focused on risk assessment, genetic testing, and high risk
surveillance with auxiliary breast imaging. He was the first non-radiologist to present data on MRI screening in a national forum, the 2006 general assembly of the American Society of Breast Disease. Along with his radiologic counterpart, Dr. Rebecca Stough, he has published some of the key papers on breast MRI. He has a special interest in the epidemiology of breast cancer screening, and has written a lay text on the topic, as well as book chapters on risk assessment and genetic testing. He serves on the Editorial Board of The Breast Journal, and is often asked to review and comment on breast MRI articles published in other journals as well.
Although in the private sector now, he is heavily involved in research strategies to better select patients for screening MRI. Over the past 15 years, he has submitted over 10,000 blood samples to various researchers working on a blood test that would signal the need for MRI in the face of negative mammograms. And, since July 2015, he has been a principal investigator on a $2.5 million R-01 NCI grant with computer scientists at the University of Oklahoma who have developed an image analysis system to select patients for MRI in spite of normal mammograms. This work has prompted a 4,000 patient clinical trial currently underway.
Alan B. Hollingsworth, MD Medical Director Mercy Breast Center, Oklahoma City
John Erban, M D,Clinical Director Tufts Cancer Center
Professor , Tufts University School of Medicine
Dr. Erban serves as Associate Director of Clinical Sciences and Clinical Director for the Tufts Cancer Center and Professor of Medicine at Tufts University School of Medicine. In this role he directs efforts to organize clinical research for the Tufts Cancer Center. Dr. Erban is an internationally known expert in breast cancer diagnosis and treatment. He has served in the past as Director of the Breast Cancer Program and Chief, Division of Hematology/Oncology (1997-2006) at Tufts Medical
Center, Clinical Director of the Gillette Center for Breast Center at Massachusetts General Hospital/Harvard Cancer Center (2007-2011) and as Associate Professor of Medicine, Harvard Medical School prior to his current position. Dr. Erban is a member of the ECOG-ACRIN Breast Committee and was a past member of the NCCN guidelines panel for Breast Cancer. He is currently Associate Editor, Amer. J. Clin. Oncology, on the editorial board of Gland Surgery, and a past member of the editorial boards of the Journal of Clinical Oncology and Oncology, Index and Reviews. He has served on the boards of the Massachusetts Society of Clinical Oncology (President 2000-2002), the Cam Neely Foundation for Cancer Care, and the Silent Spring Institute studying environmental links to cancer, which selected him for its 2015 Rachel Carson Advocacy Award.
Dr. Erban is a graduate of Harvard College (AB magna cum laude in Chemistry) and Tufts University School of Medicine and he completed his training at Hospital of the University of Pennsylvania (IM) and Tufts Medical Center (Hematology/Oncology ).
Rebecca Stough, MD, Mercy Breast Center, Oklahoma City
Launching the first comprehensive breast MRI program in Oklahoma in 2003 she facilitated the introduction of Aurora MRI devices to Mercy Hospital Oklahoma delivering cutting edge care to the community. Dr. Stough has reviewed over 20,000 breast MRI examinations. Together with Dr. Alan Hollingsworth they have published numerous papers on breast MRI.
Respected as a national and international speaker on the topics of breast
MRI and biopsies Dr. Stough holds the distinction of being selected as one of the “Top Doctors” in America and in Oklahoma from 2010 to 2018 by Castle Connolly. Additionally in 2014 and 2015 she was named as one of the “Top Doctors in Cancer in America” and American Registry “America’s Most Honored Professionals, Top 1%” in 2016.
Dr. Stough is a graduate of the University of Oklahoma for undergraduate, medical school and radiology residency. She has practiced for over 4 decades in Oklahoma.